Top J&J meds keep grooving on growth, Q2 sales data show

With the second quarter now past, number-crunchers are trying to anticipate the next round of pharma earnings. And for Johnson & Johnson ($JNJ), the word is that its fast-growing drugs will keep on delivering year-over-year growth--with one key exception.

According to Wells Fargo analysts, several J&J meds could beat expectations for Q2 sales. Among them are the SGLT2 diabetes treatments Invokana and Invokamet--which brought in $278 million in Q1--and the anticoagulant Xarelto, which has elbowed its way to the top of the warfarin-alternative market. Xarelto delivered $441 million in the first quarter, a 40% increase. Invega Sustenna, a long-acting antipsychotic, and the blockbuster anti-inflammatory med Remicade round out the bunch of pharma products expected to deliver in Q2.

As the first drugmaker to roll out earnings results every quarter, J&J is closely watched for hints at industrywide performance. The company posts its quarterly figures July 14.

Offsetting all the growing drugs would be the hepatitis C fighter Olysio, which churned out cash last year till new combo meds hit the scene. Olysio has always been expected to lose ground to cocktails from Gilead Sciences ($GILD) (Harvoni) and AbbVie ($ABBV) (Viekira Pak). Despite an FDA approval for use alongside Gilead's Sovaldi, that's likely to bear out when J&J rolls out its Q2 numbers, the Wells Fargo analysts said. For the first quarter, Olysio sales dropped by 34%.

Back on the positive side of the ledger, Nielsen data hints that J&J's consumer business in the U.S. is likely to at least hit expectations, if not surpass them, the Wells Fargo analysts said. That's after a long period of less-than-stellar results from that unit, which has struggled to get over-the-counter drug sales back on track, after a damaging round of recalls in 2009 and 2010.

J&J's growing meds face some threats going forward, however. The FDA recently warned about the risk of diabetic ketoacidosis in patients using SGLT2 meds, a class that includes Invokana. Bristol-Myers Squibb ($BMY) and Pfizer ($PFE) are fighting hard to grow Eliquis, their rival to J&J's Xarelto, and J&J and partner Bayer are fighting back with a campaign to highlight Xarelto's trial data.

- read the Barron's note

Special Reports: Top 10 drug brands by payments to doctors - Xarelto - Eliquis | Top 15 drug launch superstars - Xarelto | Top 15 pharma companies by 2014 revenue - J&J

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.